'More $MNK failed clinical studies comes weeks after OIG publishes that Acthar is a drug based on a history of "fraud and abuse. Citron believes that $MNK could be first pharma to go BK if Medicare opens its eyes' -Citron Research Tweets
Benzinga Newsdesk